Nevertheless, given the body of evidence presented, we speculate that small molecule MIF inhibitors may have therapeutic potential to ameliorate obesity-induced IR, halting the progression to T2D and non-alcoholic fatty liver disease. The gene discussed is MIF; the disease is type 2 diabetes mellitus.